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GENETICS OF COPD 
Abstract  1 
Cigarette smoking and poor air quality are the greatest risk factors for developing COPD, 2 
but growing evidence indicates genetic factors also affect predisposition to and clinical 3 
expression of disease.  With the exception of α1-Antitrypsin deficiency (AATD), a rare 4 
autosomal recessive disorder that is present in 1-3% of individuals with COPD, no single gene is 5 
associated with the development of obstructive lung disease.  Instead, a complex interplay of 6 
genetic, epigenetic, and environmental factors are the basis for persistent inflammatory 7 
responses, accelerated cell aging, cell death, and fibrosis, leading to the clinical symptoms of 8 
COPD and different phenotypic presentations. In this brief review, we discuss current 9 
understanding of the genetics of COPD, pathogenetics of AATD, epigenetic influences on 10 
development of obstructive lung disease, and how classifying COPD by phenotype can influence 11 
clinical treatment and patient outcomes.  12 
 13 
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Introduction 1 
Chronic obstructive pulmonary disease (COPD) affects approximately 6.4% of the U.S. 2 
adult population.  It is the third leading cause of death worldwide, with estimated U.S. direct 3 
costs of 49 billion dollars annually (National Center for Health Statistics, 2016).  Cigarette 4 
smoking and poor air quality are the greatest risk factors for COPD (GBD Chronic Respiratory 5 
Disease Collaborators, 2017), but there is growing evidence that genetic factors affect 6 
predisposition to and clinical expression of disease.  Having a family history (FH) of COPD 7 
markedly increases an individual's risk of developing disease, especially in people who smoke.  8 
Compared to smokers without FH of COPD, smokers whose parents had COPD were three times 9 
as likely to develop disease, but non-smokers with FH of COPD had no increased risk compared 10 
to non-smokers without FH (Zhou et al., 2013).  Thus, development of COPD is attributable to a 11 
combination of environmental and genetic factors. 12 
Genetics 13 
With the exception of α1-Antitrypsin deficiency (AATD), which occurs in 1-3% of 14 
patients with COPD, no single gene is associated with the development of obstructive lung 15 
disease (Sakornsakolpat et al., 2019).  AATD is a rare disorder typically seen in people of 16 
European ancestry.  Among people with AATD, Pulmonary disease occurs primarily as a result 17 
of abnormally shaped α1-Antitrypsin proteins (AAT) synthesized by the liver, rather than from 18 
environmental exposures.  Normally, AAT protects lung tissue from being damaged by cytotoxic 19 
enzymes secreted by roaming neutrophils, a subset of white blood cells that act as first-20 
responders in non-specific immunity. However, in AATD, the abnormal proteins do not function 21 
correctly and are instead retained in the liver, causing cirrhosis and progressive lung damage 22 
through loss of neutrophil elastase inhibition (Strnad, McElvaney, & Lomas, 2020).   23 
GENETICS OF COPD 
Misfolded AAT proteins are created due to a single DNA point mutation (change in one 24 
nucleotide base pair) at the allele SERPINA1, located on chromosome 14.  An allele is a gene 25 
pair, with one gene derived from each parent.  AAT alleles can be homozygous (same genetic 26 
sequence on chromosome 14) or heterozygous (different genetic sequences).  These variations 27 
are called protease inhibitor (PI*) types, and are used to classify AATD.  The unusual taxonomy 28 
is based on nomenclature created prior to the identification of the SERPINA1 allele (Stoller, 29 
Hupertz, & Aboussouan, 2020).   30 
PI*M is the predominant (normal) AAT allele, whereas PI*Z is the most common 31 
pathologic allele, followed by variants of PI*S, PI*I, and PI*F (Miravitlles et al., 2017).  32 
Homozygous individuals without AATD would thus have the genotype PI*MM (i.e. two normal 33 
PI*M genes).   Because AATD is an autosomal recessive disorder, an individual must have two 34 
abnormal genes to express disease.  Therefore, an individual without clinical disease could also 35 
have genotype PI*MZ or PI*MS (one normal and one disease allele).  Similarly, an individual 36 
with AATD could have genotype PI*ZZ, PI*ZS, or any other combination of two disease alleles.  37 
AATD ranges from mild to severe, depending on the pathogenic variant of the PI* mutations.  38 
For heterozygous individuals with one normal gene (PI*M), risk of developing obstructive lung 39 
disease may still be elevated, even though clinical AATD is not present.   40 
For the preceding reasons, in addition to usual COPD management, AATD should be 41 
treated with intravenous infusion of plasma-purified AAT protein to promote correct immune 42 
functioning and to slow the progression of emphysema (Miravitlles et al., 2017).  Thus, while a 43 
rare disorder, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 44 
recommend that all individuals with COPD should be tested for AATD to facilitate identification 45 
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and proper treatment of affected individuals (Global Initiative for Chornic Obstructive Lung 46 
Disease, 2021). 47 
Like asthma and other complex diseases, COPD is otherwise genetically heterogenous, 48 
with wide variability in genes, disease expression, progression, and subjective symptomatology 49 
(Corlateanu et al., 2020).  Prior to the advent of economical whole-genome sequencing, studies 50 
in COPD genetics focused primarily on identifying discrete, shared DNA variations specific to 51 
affected, related individuals (i.e. linkage studies).  This was done by examining a series of 52 
"candidate genes" thought to be related to COPD.  However, linkage studies were unsuccessful 53 
in finding any monogenic patterns of heredity, as occurs in other respiratory conditions like AAT 54 
and cystic fibrosis. 55 
With increasingly economical whole-genome sequencing, research into COPD genetics 56 
transitioned from linkage studies to genome-wide association studies (GWAS), which enable the 57 
examination of subtle variations in DNA across the entire genome, along with associations 58 
between genetic patterns, clinical traits, and treatment responsiveness (Visscher et al., 2017).  59 
Researchers using this approach have identified 156 different genes at 82 significant loci, of 60 
which >15% overlap with asthma and pulmonary fibrosis (Sakornsakolpat et al., 2019).  61 
The importance of genetics for COPD lies in the fact that inflammatory responses, which 62 
modulate disease progression and clinical presentation, are driven by DNA.  Genetic code 63 
defines how and when inflammatory mediators are created, and how noxious stimuli (e.g. 64 
particulates) are perceived and processed.  Cigarette smoking, the primary cause of COPD, 65 
exposes lung tissue to elevated levels of reactive oxygen species (ROS).  Excess ROS damages 66 
DNA and leads to increased expression of genes that control inflammation through altered 67 
activity of intracellular mediators, most commonly Nuclear factor E2-related factor (Nrf2). Nrf2 68 
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regulates hundreds of genes downstream, and is central to cellular management of oxidative 69 
stress and inflammation.  With dysregulation of Nrf2, cellular stress and aging are greatly 70 
accelerated.  These intracellular changes cause the release of pro-inflammatory mediators into 71 
the extracellular space.  Chemical messengers then attract other inflammation-regulating cells 72 
(e.g. macrophages, neutrophils, T-helper cells), which precipitate the release of additional 73 
cytotoxic chemokines and cytokines (commonly interleukins), further damaging surrounding 74 
tissues. Cumulatively, these processes form a reinforcing cycle of damage, inflammation, 75 
accelerated cell death, and fibrosis (Hikichi, Mizumura, Maruoka, & Gon, 2019).  It is also worth 76 
noting that like asthma, inflammation in COPD can be mediated by different T-helper (Th) 77 
pathways.  Inflammation in COPD typically follows Th1 and Th17 pathways (also known as 78 
Type 1 non-allergic airway inflammation), but may also be mediated by Th2 pathways.  This has 79 
been referred to as Type 2 (allergic) airway inflammation or Type 2 COPD (Oishi, Matsunaga, 80 
Shirai, Hirai, & Gon, 2020).  It has been suggested that the inflammatory mechanism via 81 
different T-helper pathways may underlie variable responsiveness to treatments; Th2 pathways 82 
are susceptible to use of inhaled corticosteroids (ICS), whereas Th1 and Th17 pathways have 83 
poor ICS-responsiveness.    84 
Epigenetics 85 
Early stage evidence indicates that epigenetic influences also play an important role in 86 
COPD development through a secondary process called DNA methylation (He, Tang, Huang, & 87 
Li, 2020).  Methylation occurs when a histone molecule becomes entangled with a portion of 88 
DNA, blocking translation and effectively "silencing" that section of genetic code.  (This can be 89 
conceptualized as bubble gum tangled in a strand of hair.)  Methylation is actually a normal 90 
process and acts as an essential on/off switch for gene expression during growth and 91 
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development.  However, abnormal methylation causes increased down-regulation of protective 92 
genes, contributing to accelerated cellular aging and death (Du et al., 2019).  Furthermore, 93 
evidence indicates that prenatal smoke exposure might also increase risk for later developing 94 
COPD through epigenetic mechanisms, as hyper-methylated DNA has been observed in the cord 95 
blood of infants exposed to cigarette smoke in utero (Krauss-Etschmann, Meyer, Dehmel, & 96 
Hylkema, 2015).  This suggests that exposure to environmental toxins could have prolonged 97 
epigenetic effects contributing to development of disease.  Because methylation is reversible, it 98 
is hypothetically amenable to targeted drug therapy, and is therefore an area of active 99 
pharmaceutical research.   100 
Clinical Phenotypes 101 
Consistent with the complex underlying genetics, clinical presentation of COPD is also 102 
highly variable.  Once treated as a single entity, COPD is now considered to be an umbrella term 103 
with several distinct phenotypes (Sakornsakolpat et al., 2019).  Phenotypes are essentially sub-104 
groups within COPD that have shared clinical characteristics of obstructive lung disease, but also 105 
have clinically important between-group differences, such as who is typically affected, patterns 106 
of symptoms and disease progression, and variable responsiveness to treatments.  Classifying 107 
and treating COPD by phenotype can help to predict outcomes and improve clinical 108 
management.   109 
The first phenotypic classification system for COPD was proposed in 1989, and included 110 
chronic bronchitis, emphysema, and asthma (Snider, 1989).  Since then, multiple taxonomies 111 
have been proposed, with currently accepted phenotypes including AATD, chronic bronchitis, 112 
emphysema, frequent exacerbator and rare exacerbator (Corlateanu et al., 2020).  Asthma and 113 
COPD are now considered fully-distinct diseases entities, albeit sharing common characteristics, 114 
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and the use of "Asthma-COPD overlap" is no longer encouraged (Global Initiative for Chornic 115 
Obstructive Lung Disease, 2021).  Emerging evidence points to additional phenotypic variations 116 
that may include a "no smoking COPD" group or overlap with other co-morbidities such as 117 
bronchiectasis.  118 
Implications for Practice 119 
Since 2011, GOLD guidelines for pharmacologic management of COPD have capitalized 120 
on four broad phenotypic groupings to determine the most appropriate first line therapy, based 121 
on responsiveness to treatment (Global Initiative for Chornic Obstructive Lung Disease, 2021).  122 
These phenotypes (GOLD Group A, B, C, D) are clustered by two clinical characteristics: risk of 123 
exacerbation with or without hospitalization (low risk/high risk) versus overall symptom burden 124 
(low symptoms/high symptoms).  While spirometric classification is assessed (grade of FEV1% 125 
predicted), it is not used as a sole factor in treatment selection, as there is no evidence to support 126 
efficacy.  Serum eosinophil counts (>100-300 cell/μL) can be predictive of ICS responsiveness 127 
and Type 2 airway inflammation, and can help to determine if inhaled or oral corticosteroids 128 
could be beneficial.  At present, biomarkers, genomic, and pharmacogenetic testing are not 129 
recommended for clinical management, with the exception of AATD testing, which should be 130 
performed once for all patients with COPD (ICD-10-CM code E88.01).  If not covered by 131 
insurance, free confidential DNA test kits are available to providers or patients directly (Alpha-1 132 
Foundation, n.d.).  Similarly, most contemporary direct-to-consumer genetic testing services can 133 
identify SERPINA1 variants (Hersh, Campbell, Scott, & Raby, 2019; Horton et al., 2019).  134 
 135 
Conclusion 136 
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In conclusion, COPD is a common, preventable inflammatory disease that occurs due to a 137 
complex interplay of genetic and environmental factors. Current understanding of COPD 138 
supports use of broad phenotypic categories to inform clinical management and predict 139 
outcomes.  Increased understanding of genetic and epigenetic factors will likely result in 140 
increasingly targeted treatment options over time. 141 
 142 
  143 
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